You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


New EU approval for GSK’s Zejula

GlaxoSmithKline’s once-daily PARP inhibitor Zejula (niraparib) has been approved by the European Commission for first-line monotherapy maintenance treatment for adults with advanced ovarian cancer.